SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Eli Lilly's biotechnology center in California
GLP-1
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.
December 23, 2024
 · 
2 min read
 · 
Kate Goodwin
Recession arrow, Graph showing business decline on led screen
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
December 20, 2024
 · 
1 min read
 · 
Kate Goodwin
External view of Bristol Myers Squibb's office California
Alzheimer’s disease
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal
BioArctic received $100 million upfront with another $1.25 billion in potential milestone payments on the line for two pyroglutamate-amyloid-beta antibodies.
December 19, 2024
 · 
1 min read
 · 
Kate Goodwin
Novo Nordisk advertising flags and logo on facade
Deals
Novo Adds Novel Approach to Cardiometabolic Pipeline With Photys Collab
Photys is eligible for up to $186 million from Novo Nordisk for its PHICS small molecules that pair a kinase to a disease-causing protein for phosphorylation.
December 18, 2024
 · 
1 min read
 · 
Kate Goodwin
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Business
Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop
The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year of consistent share value decline, analysts remain skeptical.
December 17, 2024
 · 
3 min read
 · 
Kate Goodwin
Craftsmen are using silicone adhesives for general and industrial applications.
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
 · 
6 min read
 · 
Kate Goodwin
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of death by 20%.
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Funding
Nuvig Ropes in $161M Series B From Big Pharma Players for Autoimmune Indications
California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, BMS and others for its Fc fragment immunomodulator aimed at improving autoimmune dysregulation.
December 5, 2024
 · 
1 min read
 · 
Kate Goodwin
GSK's headquarters office building in Poznan, Poland
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
One year after a potential $1.7 billion deal with Hansoh Pharma, GSK goes back to China to forge another alliance with DualityBio for another deal that could be worth up to $1 billion as it continues to build up its ADC portfolio.
December 4, 2024
 · 
1 min read
 · 
Kate Goodwin
Cancer of the brain as tumor growth diagnosis and symptoms of gliomas meningiomas astrocytomas and oligodendrogliomas as diagnosis of symptoms as a paper sculpture.
Brain cancer
Biopharma Takes on Deadly Brain Cancer After Decades of Failure
Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics and others are targeting the often-fatal brain tumor.
December 2, 2024
 · 
7 min read
 · 
Kate Goodwin
Art collage, coins, and arrow up on the red and paper background. Concept of business and financial growth.
Deals
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs
With Elevidys expansion in hand, Sarepta commits up to $10 billion to develop short interfering RNA–based drugs to build out its pipeline.
November 26, 2024
 · 
2 min read
 · 
Kate Goodwin
Washington DC, USA at the Tidal Basin during spring season at night.
Cell Therapy
CAR T for Lupus Takes Center Stage at ACR 2024
Investigational CAR T therapies stole the spotlight at the American College of Rheumatology Convergence as data presented by Bristol Myers Squibb, Kyverna Therapeutics and more highlighted their potential to effectively treat lupus.
November 19, 2024
 · 
4 min read
 · 
Kate Goodwin
Businessman jump careful on cracked or broken graph. Job opportunity and career. concept of under pressure. risk, financial, and tax
Pipeline
Neurogene Drops Batten Gene Therapy Program
After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating options for the program.
November 19, 2024
 · 
2 min read
 · 
Kate Goodwin
Crowdfunding concept with money icon and human hands in retro 80s collage mixed media vector illustration. Idea for financing business project, funding, philanthropy, cooperation, bank credit and startup development.
Business
Fledgling Obesity Biotech Metsera Raises Another $215M for Long-Acting GLP-1
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a continued appetite for these drugs.
November 13, 2024
 · 
2 min read
 · 
Kate Goodwin
Facade of AstraZeneca's office in Shanghai, China
Earnings
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the “important” U.S. market.
November 12, 2024
 · 
3 min read
 · 
Kate Goodwin
Load More